FDMT: 4dmoleculartherapeutics.com Price to Earnings Ratio

Brandmark of 4D Molecular Corp (FDMT)

4D Molecular Therapeutics attracts leading geneticists through a system of stock options and generous research funding within an academic culture. This chart of the current share price demonstrates a P/E ratio of -3.40. The business relies on the creation of precision viral capsids for targeted drug delivery to the heart and eyes, while patent protection of unique vectors eliminates pricing pressure from competitors.

FDMT - 4D Molecular Therapeutics Price to Earnings Ratio over the range 07/04/2022 - 11/16/2026

Analytical breakdowns for 4dmoleculartherapeutics.com (FDMT)

Summary company analysis:4DMT
Core merchandise of 4D Molecular Therapeutics

4D Molecular Therapeutics occupies a high-tech biopharmaceutical niche, developing precision vectors for gene therapy. By analyzing the company's P/E trajectory, an investor assesses the ratio of market value to net income. This metric serves as an indicator of the asset's resilience to market shocks, determining the break point between fair value and panic selling. A technological moat in the form of "sniper" gene delivery provides the fundamental basis for long-term position retention.

Analysis of competing companies

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|NTLA (Intellia) - Company Value to Net Income|Price to Earnings Ratio Stoke STOK|BioLife (BLFS) - Market Cap to Earnings|wavelifesciences.com - P/E Multiple|Market Cap to Net Income MAZE|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio TSHA|QURE - Market Cap to Net Income Ratio|P/E Multiple MGTX|Business Payback Period regenxbio.com|P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Earnings Multiple|PACB - Price to Earnings Ratio|Benitec (BNTC) - Price to Earnings Ratio|DSGN: P/E Multiple|RCKT: Market Price to Net Income Ratio|Price to Earnings Ratio Lexeo Therapeutics, Inc.|Market Cap to Earnings Korro Bio, Inc. KRRO|P/E Multiple EDIT|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio